Top

Published in:

01-09-2012 | Risk, Prevention, and Screening (MC Liu, Section Editor)

Tamoxifen versus Raloxifene versus Exemestane for Chemoprevention

Authors: Laura Reimers, Katherine D. Crew

Published in: Current Breast Cancer Reports | Issue 3/2012

Abstract

Clinical trial data on selective estrogen receptor modulators (SERMs) and aromatase inhibitors (AIs) have demonstrated reduced breast cancer incidence in the prevention setting among high-risk women. We conducted an extensive review of clinical trials and recent published reports of barriers to uptake of breast cancer chemoprevention, to provide health care professionals with information to improve decision making regarding chemoprevention. Despite the positive results of these trials, uptake of chemoprevention has been low due to barriers in identifying high-risk women, lack of understanding of risks and benefits, as well as concerns about side effects. Interventions designed to increase uptake have met with limited success. Clinicians can support women in informed decision making about SERMs and AIs by effectively communicating breast cancer risk and enhancing knowledge about the risks and benefits of chemoprevention. Promoting uptake and adherence to chemoprevention holds promise for reducing the public health burden of this disease.

Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Natl Cancer Inst. 1998;90:1371–88.PubMedCrossRef

Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2727–41.PubMedCrossRef

Freedman AN, Graubard BI, Rao SR, et al. Estimates of the number of US women who could benefit from tamoxifen for breast cancer chemoprevention. J Natl Cancer Inst. 2003;95:526–32.PubMedCrossRef

Ropka ME, Keim J, Philbrick JT. Patient decisions about breast cancer chemoprevention: a systematic review and meta-analysis. J Clin Oncol. 2010;28:3090–5.PubMedCrossRef

Ravdin PM. The lack, need, and opportunities for decision-making and informational tools to educate primary-care physicians and women about breast cancer chemoprevention. Cancer Prev Res. 2010;3:686–8.CrossRef

• Goss PE, Ingle JN, Ales-Martinez JE, et al. Exemestane for breast-cancer prevention in postmenopausal women. N Engl J Med. 2011;364:2381–91. This is the first chemoprevention trial of an aromatase inhibitor in high-risk postmenopausal women. The results showed a 65 % relative risk reduction in the incidence of invasive breast cancer with exemestane for 5 years, as compared with a placebo.PubMedCrossRef

Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst. 2005;97:1652–62.PubMedCrossRef

Powles TJ, Ashley S, Tidy A, Smith IE, Dowsett M. Twenty-year follow-up of the Royal Marsden randomized, double-blinded tamoxifen breast cancer prevention trial. J Natl Cancer Inst. 2007;99:283–90.PubMedCrossRef

Veronesi U, Maisonneuve P, Rotmensz N, et al. Tamoxifen for the prevention of breast cancer: late results of the Italian Randomized Tamoxifen Prevention Trial among women with hysterectomy. J Natl Cancer Inst. 2007;99:727–37.PubMedCrossRef

10.

Cuzick J, Forbes JF, Sestak I, et al. Long-term results of tamoxifen prophylaxis for breast cancer—96-month follow-up of the randomized IBIS-I trial. J Natl Cancer Inst. 2007;99:272–82.PubMedCrossRef

11.

Cummings SR, Eckert S, Krueger KA, et al. The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple outcomes of raloxifene evaluation. JAMA. 1999;281:2189–97.PubMedCrossRef

12.

Martino S, Cauley JA, Barrett-Connor E, et al. Continuing outcomes relevant to Evista: breast cancer incidence in postmenopausal osteoporotic women in a randomized trial of raloxifene. J Natl Cancer Inst. 2004;96:1751–61.PubMedCrossRef

13.

Barrett-Connor E, Mosca L, Collins P, et al. Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women. N Engl J Med. 2006;355:125–37.PubMedCrossRef

14.

Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med. 2010;362:686–96.PubMedCrossRef

15.

LaCroix AZ, Powles T, Osborne CK, et al. Breast cancer incidence in the randomized PEARL trial of lasofoxifene in postmenopausal osteoporotic women. J Natl Cancer Inst. 2010;102:1706–15.PubMedCrossRef

16.

Cummings SR, McClung M, Reginster JY, et al. Arzoxifene for prevention of fractures and invasive breast cancer in postmenopausal women. J Bone Miner Res. 2011;26:397–404.PubMedCrossRef

17.

Becker C. Another selective estrogen-receptor modulator for osteoporosis. N Engl J Med. 2010;362:752–4.PubMedCrossRef

18.

• Vogel VG, Costantino JP, Wickerham DL, et al. Update of the National Surgical Adjuvant Breast and Bowel Project Study of Tamoxifen and Raloxifene (STAR) P-2 Trial: preventing breast cancer. Cancer Prev Res. 2010;3:696–706. Updated results from the STAR trial demonstrated that raloxifene retained 76 % of the efficacy of tamoxifen in preventing invasive breast cancer with a more favorable side effect profile.CrossRef

19.

Cuzick J. Aromatase inhibitors for breast cancer prevention. J Clin Oncol. 2005;23:1636–43.PubMedCrossRef

20.

Cuzick J. Chemoprevention of breast cancer. Breast Cancer. 2008;15:10–6.PubMedCrossRef

21.

Cuzick J, Powles T, Veronesi U, et al. Overview of the main outcomes in breast-cancer prevention trials. Lancet. 2003;361:296–300.PubMedCrossRef

22.

Richardson H, Johnston D, Pater J, Goss P. The National Cancer Institute of Canada Clinical Trials Group MAP.3 trial: an international breast cancer prevention trial. Curr Oncol. 2007;14:89–96.PubMedCrossRef

23.

Cuzick J. IBIS II: a breast cancer prevention trial in postmenopausal women using the aromatase inhibitor anastrozole. Expert Rev Anticancer Ther. 2008;8:1377–85.PubMedCrossRef

24.

NCI and the STELLAR trial. Lancet. 2007;369:2134.

25.

• Waters EA, Cronin KA, Graubard BI, et al. Prevalence of tamoxifen use for breast cancer chemoprevention among U.S. women. Cancer Epidemiol Biomarkers Prev. 2010;19:443–6. Using data from the National Health Interview Survery, this study reported the low prevalence of tamoxifen use among women without breast cancer since its approval by the FDA for breast cancer chemoprevention.PubMedCrossRef

26.

Costantino JP, Gail MH, Pee D, et al. Validation studies for models projecting the risk of invasive and total breast cancer incidence. J Natl Cancer Inst. 1999;91:1541–8.PubMedCrossRef

27.

Gail MH, Costantino JP, Pee D, et al. Projecting individualized absolute invasive breast cancer risk in African American women. J Natl Cancer Inst. 2007;99:1782–92.PubMedCrossRef

28.

Matsuno RK, Costantino JP, Ziegler RG, et al. Projecting individualized absolute invasive breast cancer risk in Asian and Pacific Islander American women. J Natl Cancer Inst. 2011;103:951–61.PubMedCrossRef

29.

Abu-Rustum NR, Herbolsheimer H. Breast cancer risk assessment in indigent women at a public hospital. Gynecol Oncol. 2001;81:287–90.PubMedCrossRef

30.

Grann VR, Jacobson JS, Troxel AB, et al. Barriers to minority participation in breast carcinoma prevention trials. Cancer. 2005;104:374–9.PubMedCrossRef

31.

Tyrer J, Duffy SW, Cuzick J. A breast cancer prediction model incorporating familial and personal risk factors. Stat Med. 2004;23:1111–30.PubMedCrossRef

32.

Guerra CE, Sherman M, Armstrong K. Diffusion of breast cancer risk assessment in primary care. J Am Board Fam Med. 2009;22:272–9.PubMedCrossRef

33.

Sabatino SA, McCarthy EP, Phillips RS, Burns RB. Breast cancer risk assessment and management in primary care: provider attitudes, practices, and barriers. Cancer Detect Prev. 2007;31:375–83.PubMedCrossRef

34.

• Owens WL, Gallagher TJ, Kincheloe MJ, Ruetten VL. Implementation in a large health system of a program to identify women at high risk for breast cancer. J Oncol Pract. 2011;7:85–8. This study implemented routine screening with the Gail model for high-risk women seen in a women's center. Over 15 % of women met high-risk criteria, but only 2 % of eligible women agreed to a SERM for chemoprevention.PubMedCrossRef

35.

Dubin-Rhodin A, Greenlee H, Terry MB, et al. Development of the Breast Cancer Family-Based Intervention Trial (BFIT) database. Washington, DC: American Society of Preventive Oncology; 2012.

36.

Bober SL, Hoke LA, Duda RB, et al. Decision-making about tamoxifen in women at high risk for breast cancer: clinical and psychological factors. J Clin Oncol. 2004;22:4951–7.PubMedCrossRef

37.

Melnikow J, Paterniti D, Azari R, et al. Preferences of Women Evaluating Risks of Tamoxifen (POWER) study of preferences for tamoxifen for breast cancer risk reduction. Cancer. 2005;103:1996–2005.PubMedCrossRef

38.

Taylor R, Taguchi K. Tamoxifen for breast cancer chemoprevention: low uptake by high-risk women after evaluation of a breast lump. Ann Fam Med. 2005;3:242–7.PubMedCrossRef

39.

Fagerlin A, Zikmund-Fisher BJ, Nair V, et al. Women's decisions regarding tamoxifen for breast cancer prevention: responses to a tailored decision aid. Breast Cancer Res Treat. 2010;119:613–20.PubMedCrossRef

40.

Metcalfe KA, Snyder C, Seidel J, et al. The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Fam Cancer. 2005;4:97–103.PubMedCrossRef

41.

Salant T, Ganschow PS, Olopade OI, Lauderdale DS. "Why take it if you don't have anything?" breast cancer risk perceptions and prevention choices at a public hospital. J Gen Intern Med. 2006;21:779–85.PubMedCrossRef

42.

Port ER, Montgomery LL, Heerdt AS, Borgen PI. Patient reluctance toward tamoxifen use for breast cancer primary prevention. Ann Surg Oncol. 2001;8:580–5.PubMedCrossRef

43.

Stacey D, O'Connor AM, DeGrasse C, Verma S. Development and evaluation of a breast cancer prevention decision aid for higher-risk women. Health Expect. 2003;6:3–18.PubMedCrossRef

44.

Day R, Ganz PA, Costantino JP, et al. Health-related quality of life and tamoxifen in breast cancer prevention: a report from the National Surgical Adjuvant Breast and Bowel Project P-1 Study. J Clin Oncol. 1999;17:2659–69.PubMed

45.

Land SR, Wickerham DL, Costantino JP, et al. Patient-reported symptoms and quality of life during treatment with tamoxifen or raloxifene for breast cancer prevention: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA. 2006;295:2742–51.PubMedCrossRef

46.

Buzdar A, Howell A, Cuzick J, et al. Comprehensive side-effect profile of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: long-term safety analysis of the ATAC trial. Lancet Oncol. 2006;7:633–43.PubMedCrossRef

47.

Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet. 2007;369:559–70.PubMedCrossRef

48.

Thurlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med. 2005;353:2747–57.PubMedCrossRef

49.

Kaplan CP, Haas JS, Perez-Stable EJ, et al. Factors affecting breast cancer risk reduction practices among California physicians. Prev Med. 2005;41:7–15.PubMedCrossRef

50.

Rondanina G, Puntoni M, Severi G, et al. Psychological and clinical factors implicated in decision making about a trial of low-dose tamoxifen in hormone replacement therapy users. J Clin Oncol. 2008;26:1537–43.PubMedCrossRef

51.

Freedman AN, Yu B, Gail MH, et al. Benefit/risk assessment for breast cancer chemoprevention with raloxifene or tamoxifen for women age 50 years or older. J Clin Oncol. 2011;29:2327–33.PubMedCrossRef

52.

Lin JH, Zhang SM, Manson JE. Predicting adherence to tamoxifen for breast cancer adjuvant therapy and prevention. Cancer Prev Res. 2011;4:1360–5.CrossRef

53.

Dezentje VO, van Blijderveen NJ, Gelderblom H, et al. Effect of concomitant CYP2D6 inhibitor use and tamoxifen adherence on breast cancer recurrence in early-stage breast cancer. J Clin Oncol. 2010;28:2423–9.PubMedCrossRef

54.

Partridge AH, Wang PS, Winer EP, Avorn J. Nonadherence to adjuvant tamoxifen therapy in women with primary breast cancer. J Clin Oncol. 2003;21:602–6.PubMedCrossRef

55.

Hershman DL, Kushi LH, Shao T, et al. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010;28:4120–8.PubMedCrossRef

56.

Veronesi A, Pizzichetta MA, Ferlante MA, et al. Tamoxifen as adjuvant after surgery for breast cancer and tamoxifen or placebo as chemoprevention in healthy women: different compliance with treatment. Tumori. 1998;84:372–5.PubMed

57.

Land SR, Cronin WM, Wickerham DL, et al. Cigarette smoking, obesity, physical activity, and alcohol use as predictors of chemoprevention adherence in the national surgical adjuvant breast and bowel project p-1 breast cancer prevention trial. Cancer Prev Res. 2011;4:1393–400.CrossRef

58.

Moy B, Richardson H, Johnston D, et al. NCIC CTG MAP.3: enrollment and study drug adherence of ethnic minority women in a breast cancer prevention trial. Breast Cancer Res Treat. 2007;106:S141–2.

59.

• Fagerlin A, Dillard AJ, Smith DM, et al. Women's interest in taking tamoxifen and raloxifene for breast cancer prevention: response to a tailored decision aid. Breast Cancer Res Treat. 2011;127:681–8. This is a randomized controlled trial of a tailored on-line decision aid to inform women about breast cancer chemoprevention, which resulted in low SERM uptake.PubMedCrossRef

60.

Loehberg CR, Jud SM, Haeberle L, et al. Breast cancer risk assessment in a mammography screening program and participation in the IBIS-II chemoprevention trial. Breast Cancer Res Treat. 2010;121:101–10.PubMedCrossRef

61.

Tchou J, Hou N, Rademaker A, et al. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer. 2004;100:1800–6.PubMedCrossRef

62.

Goldenberg VK, Seewaldt VL, Scott V, et al. Atypia in random periareolar fine-needle aspiration affects the decision of women at high risk to take tamoxifen for breast cancer chemoprevention. Cancer Epidemiol Biomarkers Prev. 2007;16:1032–4.PubMedCrossRef

63.

McKay A, Latosinsky S, Martin W. Acceptance of tamoxifen chemoprevention by physicians and women at risk. Cancer. 2005;103:209–10.PubMedCrossRef

64.

Reimers LL, Campbell J, Hershman DL, et al. Uptake of selective estrogen receptor modulators and other breast cancer prevention strategies among high-risk women seen in a breast center. San Antonio Breast Cancer Symposium, 2011.

65.

Visvanathan K, Chlebowski RT, Hurley P, et al. American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol. 2009;27:3235–58.PubMedCrossRef

66.

Bevers TB, Armstrong DK, Arun B, et al. Breast cancer risk reduction. J Natl Compr Canc Netw. 2010;8:1112–46.PubMed

67.

Meyskens Jr FL, Curt GA, Brenner DE, et al. Regulatory approval of cancer risk-reducing (chemopreventive) drugs: moving what we have learned into the clinic. Cancer Prev Res. 2011;4:311–23.CrossRef

68.

Cuzick J, DeCensi A, Arun B, et al. Preventive therapy for breast cancer: a consensus statement. Lancet Oncol. 2011;12:496–503.PubMedCrossRef

69.

Cuzick J, Warwick J, Pinney E, et al. Tamoxifen-induced reduction in mammographic density and breast cancer risk reduction: a nested case-control study. J Natl Cancer Inst. 2011;103:744–52.PubMedCrossRef

Title: Tamoxifen versus Raloxifene versus Exemestane for Chemoprevention
Authors: Laura Reimers
Katherine D. Crew
Publication date: 01-09-2012
Publisher: Current Science Inc.
Published in: Current Breast Cancer Reports / Issue 3/2012
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-012-0082-8

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2012

Prophylactic Mastectomy and Risk-Reducing Salpingo-oophorectomy in BRCA1/2 Mutation Carriers

Options for Surgical Prophylaxis and Reconstruction

Role of Mammography versus Magnetic Resonance Imaging for Breast Cancer Screening

Comparison of Random Periareolar Fine Needle Aspirate versus Ductal Lavage for Risk Assessment and Prevention of Breast Cancer

Analysis of Cyclin D1 in Breast Cancer: A Call to Arms

Is HER2 Through?

Keynote webinar | Spotlight on antibody–drug conjugates in cancer